References
Hadano N, Murakami Y, Uemura K, et al. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer. Br. J. Cancer. 2016;115:59–65.
Del Re M, Vivaldi C, Rofi E, et al. Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer. Sci. Rep. 2017;7:7931.
Yamada T, Nakamori S, Ohzato H, et al. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. Clin Cancer Res. 1998;4:1527–32.
Uemura T, Hibi K, Kaneko T, et al. Detection of K-ras mutations in the plasma DNA of pancreatic cancer patients. J. Gastroenterol. 2004;39:56–60.
Yamaguchi T, Uemura K, Murakami Y, et al. Clinical implications of pre- and postoperative circulating tumor DNA in patients with resected pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-09278-9.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
There are no conflicts of interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Yamaguchi, T., Uemura, K. & Takahashi, S. ASO Author Reflections: Clinical Implications of Circulating Tumor DNA in Pancreatic Cancer Patients. Ann Surg Oncol 28, 3145–3146 (2021). https://doi.org/10.1245/s10434-020-09317-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-020-09317-5